ASTRAZENECA (ZEG.SG) (ZEG STU) stock market data APIs
€120.3436
-1.85(-1.5%)
as of July 4, 2025
Try our APIs with
free plan!
ASTRAZENECA (ZEG.SG) Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ZEG.SG.
Prev. Close
120.3436
Open
118.4911
High
120.4466
Low
118.4911
52 wk Range
110-156.0378
Market Cap
148 612 M
Dividends (Yield)
0.0087
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ASTRAZENECA (ZEG.SG) data using free add-ons & libraries
Get ASTRAZENECA (ZEG.SG) Fundamental Data
ASTRAZENECA (ZEG.SG) Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ASTRAZENECA (ZEG.SG) News
New
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
AstraZeneca recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about intern...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU isthe first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient ...
Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s
(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative...
Six FTSE 100 stock ideas for the second quarter, according to Barclays
While uncertainty remains high as US president Donald Trump's fast-moving tariff agenda has prompted big moves in stock markets, Barclays (BARC.L) analysts have highlighted six UK stock ideas for the ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
